此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Multicomponent Exercise Program in Women With Hypertension

2026年10月27日 更新者:Javier Fernando Rodríguez Triana、Universidad Pedagogica Nacional, Colombia

Effects of a Multicomponent Physical Exercise Program on Blood Pressure Parameters, Cardiorespiratory Capacity, Handgrip Strength and Quality of Life in Hypertensive Women With Cardiovascular Risk

This study tested whether a 12-week supervised multicomponent exercise program is associated with changes in blood pressure, estimated cardiorespiratory fitness, handgrip strength and health-related quality of life in women aged 45 to 59 years with hypertension. The program combined strength training, aerobic exercise (brisk walking or light jogging), controlled breathing and flexibility, in three sessions per week of about 60 minutes, mainly in community spaces in Bogotá, Colombia, with a hybrid option for women who could not attend in person. Thirty-two women were assigned, by convenience according to their availability for the class schedule, to an exercise group (n = 16) or to a control group that kept its usual activities (n = 16). Systolic and diastolic blood pressure, estimated cardiorespiratory fitness (Rockport 1-mile walk test), handgrip strength (dynamometer) and quality of life (SF-36 questionnaire) were measured before and after the 12 weeks.

研究概览

详细说明

Design: non-randomized, parallel-group, quasi-experimental study with pre- and post-intervention measurements in an exercise group and a control group.

Recruitment and setting: participants were recruited in Bogotá, Colombia, during the two months before the baseline assessment (approximately from late April 2026), through an information session and written informed consent. The program was delivered mainly in community spaces in the Restrepo neighborhood (Antonio Nariño locality), with a hybrid option for participants who could not attend in person.

Timeline: baseline assessments were carried out on 24 and 26 June 2026 and the program started on 30 June 2026. Post-intervention assessments were carried out in week 12: blood pressure, handgrip strength and anthropometry on 17 September 2026 (about 48 hours after the last session), the Rockport walk test on 19 September 2026, and the SF-36 questionnaire was completed by participants between 17 and 19 September 2026.

Program: the exercise program followed the FITT-VP model (frequency, intensity, time, type, volume and progression), with progression in three phases (anatomical conditioning, development and consolidation). Exercise intensity was monitored with the OMNI perceived exertion scale (0-10), and heart rate was checked with a chest strap in a random subset of participants. In week 6, the exercise group completed tolerance check tests (blood pressure, cardiorespiratory fitness and handgrip strength) only to decide whether the plan needed adjustments; these were not part of the confirmatory analysis. The control group maintained its usual activities.

Analysis: the main analysis was a 2 x 2 mixed ANOVA (Group x Time), with the Group x Time interaction as the key parameter. An ANCOVA on post-intervention diastolic blood pressure, with baseline diastolic blood pressure as covariate, was added after a baseline imbalance was detected and was not specified in the original protocol.

REGISTRATION NOTE: this study was registered retrospectively, after data collection had been completed.

研究类型

介入性

注册 (实际的)

32

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Bogota D.C.
      • Bogotá、Bogota D.C.、哥伦比亚
        • Community spaces, Restrepo neighborhood (Antonio Nariño locality)

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

45年 至 59年 (成人)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria:

  • Women aged 45 to 59 years
  • Medically confirmed diagnosis of essential arterial hypertension
  • Medical clearance to practice exercise
  • Low physical activity level or sedentary
  • Ability to sign informed consent
  • Availability to comply with the intervention program
  • Stable clinical condition
  • No use of substances that alter the physiological response

Exclusion Criteria:

  • Men or outside the age range
  • Secondary or unconfirmed hypertension
  • Medical contraindication to exercise
  • Recent participation in structured exercise programs
  • Cognitive difficulty or refusal to participate
  • Low adherence or inability to attend
  • Recent cardiovascular events
  • Use of substances that interfere with the study

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Multicomponent exercise program

Supervised multicomponent exercise program for 12 weeks, three sessions per week (up to 60 minutes), combining strength training, aerobic exercise (brisk walking, rhythmic cardio-boxing and interval work), controlled breathing and flexibility. Program planned with the FITT-VP model and progressed in three phases (anatomical conditioning, development and consolidation). Delivered mainly in community spaces, with a hybrid option for participants who could not attend in person.

Supervised program of 12 weeks, three sessions per week (up to 60 minutes). Components: muscular strength training with elastic bands and body weight (squat, step-up, incline push-up, band row, farmer walk); aerobic exercise (brisk walking or jogging, rhythmic cardio-boxing and interval work at a prescribed intensity); controlled breathing (square breathing 4x4x4x4, diaphragmatic, pursed-lip and slow breathing) and flexibility (pectoral, hamstring, iliopsoas and lateral trunk stretches). Load progressed over three phases. Intensity was monitored with the OMNI perceived exertion scale (0-10) and, in a random subset of participants, with a chest-strap heart rate monitor (Polar H10).

无干预:Control

Women with hypertension who maintained their usual activities during the 12 weeks and received no exercise program. They were assessed before and after the same period with the same instruments as the exercise group.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in resting systolic blood pressure (SBP) from baseline to week 12
大体时间:Baseline (24 and 26 June 2026) and week 12 of the program (17 September 2026)

Resting systolic blood pressure in mmHg, measured with an automated upper-arm monitor (Omron HEM-716DT2). Three measurements at rest (at least 5 minutes of rest); the mean of the second and third measurements is used. Change = post-intervention value minus baseline value. Between-group difference in change tested with the Group x Time interaction of a 2 x 2 mixed ANOVA.

Baseline (24 and 26 June 2026) and week 12 of the program (17 September 2026)
Change in resting diastolic blood pressure (DBP) from baseline to week 12
大体时间:Baseline (24 and 26 June 2026) and week 12 of the program (17 September 2026)

Resting diastolic blood pressure in mmHg, measured with an automated upper-arm monitor (Omron HEM-716DT2). Three measurements at rest (at least 5 minutes of rest); the mean of the second and third measurements is used. Change = post-intervention value minus baseline value. Tested with the Group x Time interaction of a 2 x 2 mixed ANOVA. An ANCOVA on post-intervention DBP with baseline DBP as covariate was added after a baseline imbalance was detected and was not specified in the original protocol.

Baseline (24 and 26 June 2026) and week 12 of the program (17 September 2026)

次要结果测量

结果测量
措施说明
大体时间
Change in estimated cardiorespiratory fitness (estimated VO2) from baseline to week 12
大体时间:Baseline (24 and 26 June 2026) and week 12 of the program (19 September 2026)

Estimated VO2 in ml/kg/min from the Rockport 1-mile (1,609 m) walk test, using walking time and final heart rate (recorded with a chest strap, Polar H10) in the equation of Kline et al. (1987). This is an estimate and not a direct measurement of maximal oxygen uptake. Change = post-intervention minus baseline.

Baseline (24 and 26 June 2026) and week 12 of the program (19 September 2026)
Change in handgrip strength, dominant hand, from baseline to week 12
大体时间:Baseline (24 and 26 June 2026) and week 12 of the program (17 September 2026)

Maximal handgrip strength of the dominant hand in kg, measured with a hand dynamometer (Camry EH101). Three attempts; the maximum value is recorded. Change = post-intervention minus baseline.

Baseline (24 and 26 June 2026) and week 12 of the program (17 September 2026)
Change in handgrip strength, non-dominant hand, from baseline to week 12
大体时间:Baseline (24 and 26 June 2026) and week 12 of the program (17 September 2026)

Maximal handgrip strength of the non-dominant hand in kg, measured with a hand dynamometer (Camry EH101). Three attempts; the maximum value is recorded. Change = post-intervention minus baseline.

Baseline (24 and 26 June 2026) and week 12 of the program (17 September 2026)
Change in health-related quality of life (SF-36 domain scores) from baseline to week 12
大体时间:Baseline (June 2026) and week 12 of the program (completed between 17 and 19 September 2026)

SF-36 questionnaire, scored 0-100 for each of its eight domains (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health); higher scores indicate better perceived health. Each domain was analyzed separately; no global SF-36 score was calculated. Change = post-intervention minus baseline.

Baseline (June 2026) and week 12 of the program (completed between 17 and 19 September 2026)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年6月24日

初级完成 (实际的)

2026年9月17日

研究完成 (实际的)

2026年9月19日

研究注册日期

首次提交

2026年10月27日

首先提交符合 QC 标准的

2026年10月27日

首次发布 (实际的)

2026年11月3日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年10月27日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data will not be shared because the informed consent guaranteed participants that only aggregated results would be published and that identifiable data would be accessible only to the research team.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅